PMA device
EVOQUE Tricuspid Valve Replacement System
Edwards Lifesciences, LLC · Percutaneously Delivered Prostheses And Tricuspid Valves (NPW, Class III) · First FDA decision Mar 15, 2024, newest Sep 16, 2026Tricuspid regurgitation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
PMA pathway
Device trials
9
Naming "EVOQUE"
MAUDE reports
1,085
Brand "EVOQUE", since 2015
PubMed studies
128
Mentioning "EVOQUE"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing EVOQUE Tricuspid Valve Replacement System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- EVOQUE Tricuspid Valve Replacement SystemPMA supplement
P230013-S027 · Decided Sep 16, 2026 · 180 days after receipt · Normal 180 Day Track
Device type: Percutaneously Delivered Prostheses and Tricuspid Valves (NPW) · Cardiology
- EVOQUE Tricuspid Delivery System: 9850TDS EVOQUE dilator kit: 9850DK EVOQUE loading system: 9850LSPMA supplement
P230013-S012 · Decided Jun 4, 2025 · 68 days after receipt · Normal 180 Day Track No User Fee
Device type: Percutaneously Delivered Prostheses and Tricuspid Valves (NPW) · Cardiology
- EVOQUE Transcatheter Tricuspid Delivery System, EVOQUE Dilator Kit, EVOQUE Loading SystemPMA supplement
P230013-S001 · Decided Mar 15, 2024 · 18 days after receipt · Normal 180 Day Track No User Fee
Device type: Percutaneously Delivered Prostheses and Tricuspid Valves (NPW) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Transcatheter Tricuspid Valve Replacement (TTVR)National analysisReview closedCAG-00467NUpdated Sep 24, 2026
- Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER)National analysisReview closedCAG-00468NUpdated Sep 23, 2026
- Transcatheter Edge-to-Edge Repair for Tricuspid Valve Regurgitation (T-TEER)National determinationOn the books20.38Updated Jun 2, 2026
- Transcatheter Tricuspid Valve Replacement (TTVR)National determinationOn the books20.37Updated Jun 2, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "EVOQUE", any status and sponsor, newest update first.
- Transcatheter Tricuspid Valve Replacement With the Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System in Severe Tricuspid RegurgitationPivotal-lookingRecruiting
Medtronic CardiovascularPublic (MDT)
NCT07321899 · 1,186 participants (planned) · Start Sep 11, 2026 · Primary completion Sep 2031
Device: Medtronic Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR) System; Edwards EVOQUE Tricuspid Valve Replacement (TTVR) System · For: Severe Tricuspid Regurgitation
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 20 sites in all
- VDyne TriNova Transcatheter Tricuspid Valve Replacement Study to Evaluate Safety and Clinical Efficacy in Patients With Symptomatic Severe Tricuspid Valve Regurgitation (TRIVITA Pivotal Trial)Pivotal-lookingRecruiting
VDyne, Inc.Not on our public-company list
NCT07516444 · 520 participants (planned) · Start Jul 28, 2026 · Primary completion Jun 2029
Device: Transcatheter Tricuspid Valve Replacement (TTVR) with VDyne TriNova System; Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE System · For: Tricuspid Valve Regurgitation; Tricuspid Valve Disease; Cardiovascular Diseases (CVD) and 5 more
Sites: Phoenix, Arizona; Scottsdale, Arizona; San Francisco, California · 12 sites in all
- Tricuspid Regurgitation Treatment With LAPLACE Transcatheter Tricuspid Valve Replacement SystemPivotal-lookingRecruiting
Laplace Interventional, IncNot on our public-company list
NCT07687485 · 700 participants (planned) · Start Sep 4, 2026 · Primary completion Sep 2029
Device: Transcatheter Tricuspid Valve Replacement (TTVR) with Laplace TTVR System; Transcatheter Tricuspid Valve Replacement (TTVR) with Edwards EVOQUE TTVR System · For: Severe Tricuspid Valve Regurgitation; Tricuspid Valve Regurgitation; Tricuspid Valve Disease and 5 more
Sites: Tulsa, Oklahoma; Kingsport, Tennessee
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "EVOQUE", and for the whole product code for context.
This brand
1,085 reports: 30 malfunction, 967 injury, 88 death
Whole product code NPW
1,088 reports: 30 malfunction, 970 injury, 88 death
Newest reports for this brand
- EVOQUE ValveInjury
2015691-2026-19830 · Received Oct 29, 2026 · Event dated Sep 30, 2026
Device type: Percutaneously Delivered Prostheses And Tricuspid Valves (NPW)
Device problem as coded: Malposition of Device
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- EVOQUE ValveInjury
2015691-2026-19849 · Received Oct 29, 2026 · Event dated Sep 30, 2026
Device type: Percutaneously Delivered Prostheses And Tricuspid Valves (NPW)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Thrombosis/Thrombus
2015691-2026-19769 · Received Oct 27, 2026 · Event dated Oct 6, 2026
Device type: Percutaneously Delivered Prostheses And Tricuspid Valves (NPW)
Device problem as coded: Patient Device Interaction Problem
Patient problem as coded: Arrhythmia
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Edwards EVOQUE tricuspid delivery system REF:9850TDS Sterile EOOpen, Classified
Z-2172-2026 · Started Mar 27, 2026 · Posted by FDA May 13, 2026
Reason given: Labeling update to provide warning if functionality of the valve replacement delivery system is compromised.
Cause as FDA categorized it: Labeling design · Device type: Percutaneously Delivered Prostheses And Tricuspid Valves (NPW)
Published research
The most relevant PubMed records for "EVOQUE"[tiab]. The summary above synthesizes these.
- EVOQUE Tricuspid Valve Replacement System: State-of-the-Art Screening and Intraprocedural Guidance.
Hahn RT, Makkar R, Makar M, et al. · JACC Cardiovasc Interv · 2024Review
- EVOQUE Transcatheter Tricuspid Valve Replacement: 5 Years On.
Fam NP, Alnasser S, Deva DP, et al. · JACC Cardiovasc Interv · 2024
- EVOQUE Transcatheter Tricuspid Valve Replacement for Double TriClip Single-Leaflet Device Attachment.
Traynor BP, Alnasser S, Bisleri G, et al. · JACC Cardiovasc Interv · 2024
- Atrioventricular Block After EVOQUE Transcatheter Tricuspid Valve Replacement.
Rangavajla G, Patel R, Nguyen F, et al. · Struct Heart · 2025
- Transcatheter Tricuspid Valve Replacement With the EVOQUE System: 1-Year Outcomes of a Multicenter, First-in-Human Experience.
Webb JG, Chuang AM, Meier D, et al. · JACC Cardiovasc Interv · 2022Multicenter Study, Research Support, Non-U.S. Gov't
- Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study.
Kodali S, Hahn RT, Makkar R, et al. · Eur Heart J · 2023Research Support, Non-U.S. Gov't
- Transjugular Approach for Evoque Transcatheter Tricuspid Valve Replacement in Patients With Challenging Anatomy.
Fang JX, Villablanca PA, Frisoli TM, et al. · Circ Cardiovasc Interv · 2025
- Early Outcomes of Real-World Transcatheter Tricuspid Valve Replacement.
Angellotti D, Mattig I, Samim D, et al. · JACC Cardiovasc Interv · 2025Multicenter Study, Observational Study
- Evoque Transcatheter Tricuspid Valve Replacement for a Tetralogy of Fallot Patient.
Madanat L, Jabri A, Bloomingdale R, et al. · JACC Cardiovasc Interv · 2025
- Transfemoral Transcatheter Tricuspid Valve Replacement.
Fam NP, Ong G, Deva DP, et al. · JACC Cardiovasc Interv · 2020Case Reports, Video-Audio Media
- Evoque Tricuspid Replacement in a Patient With Failed Cardioband Transcatheter Tricuspid Annuloplasty.
Jayanthi R, Rajagopal D, Alami AK, et al. · JACC Cardiovasc Interv · 2025
- Early Leaflet Thrombosis Following EVOQUE Transcatheter Tricuspid Valve Replacement.
Skalidis I, Esposito L, Boiago M, et al. · JACC Cardiovasc Interv · 2025
Other devices of this type
Also filed under product code NPW.
- Edwards EVOQUE Tricuspid Valve Replacement SystemEdwards Lifesciences, LLC · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.